Compare Stocks: HOWL, VYGR, ORGO, and NBP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HOWL Werewolf Therapeutics	$0.97 +0.2%	$0.63	$0.27 ▼ $2.38	$46.90M	0.51	17.20 million shs	1.23 million shs
NBP I-Mab	$1.60 -1.8%	$1.77	$1.46 ▼ $6.79	$185.04M	1.5	239,301 shs	197,530 shs
ORGO Organogenesis	$1.42 +4.4%	$1.98	$1.34 ▼ $7.08	$182.72M	1.29	647,896 shs	1.00 million shs
VYGR Voyager Therapeutics	$3.09 +1.6%	$3.23	$2.93 ▼ $5.55	$190.40M	1.32	403,889 shs	538,080 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HOWL Werewolf Therapeutics	0.00%	-1.73%	+123.79%	+174.69%	-31.07%
NBP I-Mab	0.00%	+0.63%	-16.23%	+6.67%	+159,999,900.00%
ORGO Organogenesis	0.00%	-4.70%	-22.83%	-41.80%	-69.26%
VYGR Voyager Therapeutics	0.00%	-3.13%	-6.93%	-16.94%	-27.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HOWL Werewolf Therapeutics	$0.97 +0.2%	$0.63	$0.27 ▼ $2.38	$46.90M	0.51	17.20 million shs	1.23 million shs
NBP I-Mab	$1.60 -1.8%	$1.77	$1.46 ▼ $6.79	$185.04M	1.5	239,301 shs	197,530 shs
ORGO Organogenesis	$1.42 +4.4%	$1.98	$1.34 ▼ $7.08	$182.72M	1.29	647,896 shs	1.00 million shs
VYGR Voyager Therapeutics	$3.09 +1.6%	$3.23	$2.93 ▼ $5.55	$190.40M	1.32	403,889 shs	538,080 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HOWL Werewolf Therapeutics	0.00%	-1.73%	+123.79%	+174.69%	-31.07%
NBP I-Mab	0.00%	+0.63%	-16.23%	+6.67%	+159,999,900.00%
ORGO Organogenesis	0.00%	-4.70%	-22.83%	-41.80%	-69.26%
VYGR Voyager Therapeutics	0.00%	-3.13%	-6.93%	-16.94%	-27.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HOWL Werewolf Therapeutics	2.14	Hold	$4.00	314.51% Upside
NBP I-Mab	2.00	Hold	$9.00	462.50% Upside
ORGO Organogenesis	1.67	Reduce	$4.33	205.16% Upside
VYGR Voyager Therapeutics	2.75	Moderate Buy	$16.50	433.98% Upside

Current Analyst Ratings Breakdown

Latest HOWL, VYGR, ORGO, and NBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	HOWL Werewolf Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/4/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	NBP I-Mab	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/27/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/21/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
8/20/2026	NBP I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$9.00
8/10/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/7/2026	ORGO Organogenesis	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$3.00 ➝ $2.00
7/20/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/13/2026	VYGR Voyager Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HOWL Werewolf Therapeutics	$1.88M	24.95	N/A	N/A	$0.51 per share	1.89
NBP I-Mab	$3.89M	47.57	N/A	N/A	$2.00 per share	0.80
ORGO Organogenesis	$564.17M	0.32	$0.65 per share	2.19	$2.36 per share	0.60
VYGR Voyager Therapeutics	$40.37M	4.72	N/A	N/A	$3.53 per share	0.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HOWL Werewolf Therapeutics	-$60.82M	-$0.76	N/A	N/A	N/A	N/A	-166.99%	-59.88%	11/3/2026 (Estimated)
NBP I-Mab	-$46.27M	-$0.36	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	$37.03M	-$0.86	N/A	N/A	N/A	-19.94%	-23.89%	-11.13%	11/5/2026 (Estimated)
VYGR Voyager Therapeutics	-$119.72M	-$1.80	N/A	N/A	N/A	-312.63%	-57.92%	-45.00%	11/9/2026 (Estimated)

Latest HOWL, VYGR, ORGO, and NBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	Q2 2026	NBP I-Mab	N/A	-$0.1610	N/A	-$0.1610	N/A	N/A
8/6/2026	Q2 2026	ORGO Organogenesis	-$0.35	-$0.71	-$0.36	-$0.77	$54.27 million	$43.76 million
8/6/2026	Q2 2026	VYGR Voyager Therapeutics	-$0.4838	-$0.40	+$0.0838	-$0.40	$4.52 million	$3.17 million
7/31/2026	Q2 2026	HOWL Werewolf Therapeutics	-$0.28	$0.08	+$0.36	$0.08	$21.00 million	$21.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
NBP I-Mab	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HOWL Werewolf Therapeutics	N/A	2.91	2.91
NBP I-Mab	N/A	7.64	8.09
ORGO Organogenesis	0.07	3.52	3.00
VYGR Voyager Therapeutics	N/A	7.51	7.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HOWL Werewolf Therapeutics	64.84%
NBP I-Mab	38.38%
ORGO Organogenesis	49.57%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
HOWL Werewolf Therapeutics	23.60%
NBP I-Mab	22.10%
ORGO Organogenesis	18.80%
VYGR Voyager Therapeutics	12.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HOWL Werewolf Therapeutics	14	48.60 million	37.13 million	Optionable
NBP I-Mab	30	115.65 million	90.09 million	N/A
ORGO Organogenesis	854	128.68 million	104.48 million	Optionable
VYGR Voyager Therapeutics	141	61.62 million	53.79 million	Optionable

HOWL, VYGR, ORGO, and NBP Headlines

Recent News About These Companies

Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

September 10, 2026 | seekingalpha.com

BlackRock Inc. Takes $18.10 Million Position in Voyager Therapeutics, Inc. $VYGR

September 4, 2026 | marketbeat.com

Voyager to Present at Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

Voyager Therapeutics (NASDAQ:VYGR) Stock Price Crosses Above Fifty Day Moving Average - Here's What Happened

August 29, 2026 | marketbeat.com

TD Cowen Remains a Buy on Voyager Therapeutics (VYGR)

August 24, 2026 | theglobeandmail.com

Voyager Therapeutics (NASDAQ:VYGR) Stock Price Passes Above 50-Day Moving Average - What's Next?

August 21, 2026 | marketbeat.com

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Voyager Reports Second Quarter 2026 Financial and Operating Results

August 6, 2026 | finance.yahoo.com

Voyager Therapeutics: Q2 Earnings Snapshot

August 6, 2026 | khou.comK

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

August 4, 2026 | theglobeandmail.com

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

July 13, 2026 | markets.businessinsider.com

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026

July 13, 2026 | globenewswire.com

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money

July 2, 2026 | aol.comA

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money

July 2, 2026 | 247wallst.com

Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside

June 30, 2026 | finance.yahoo.com

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

June 29, 2026 | markets.businessinsider.com

Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

June 29, 2026 | globenewswire.com

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

June 11, 2026 | globenewswire.com

Voyager Therapeutics Highlights 2026 CNS Pipeline and Strategy

June 10, 2026 | theglobeandmail.com

Voyager Therapeutics Expands Authorized Shares After Stockholder Vote

June 10, 2026 | tipranks.com

Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation

June 9, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, VYGR, ORGO, and NBP Company Descriptions

Werewolf Therapeutics NASDAQ:HOWL

$0.96 +0.00 (+0.21%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.98 +0.01 (+1.24%)

As of 09/18/2026 07:42 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

I-Mab NASDAQ:NBP

$1.60 -0.03 (-1.84%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.65 +0.05 (+3.37%)

As of 09/18/2026 07:53 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Organogenesis NASDAQ:ORGO

$1.42 +0.06 (+4.41%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.44 +0.02 (+1.06%)

As of 09/18/2026 07:36 PM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Voyager Therapeutics NASDAQ:VYGR

$3.09 +0.05 (+1.64%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.07 -0.02 (-0.71%)

As of 09/18/2026 07:59 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOWL, VYGR, ORGO, and NBP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOWL, VYGR, ORGO, and NBP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOWL, VYGR, ORGO, and NBP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, VYGR, ORGO, and NBP Company Descriptions

Werewolf Therapeutics NASDAQ:HOWL

I-Mab NASDAQ:NBP

Organogenesis NASDAQ:ORGO

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOWL, VYGR, ORGO, and NBP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOWL, VYGR, ORGO, and NBP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOWL, VYGR, ORGO, and NBP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, VYGR, ORGO, and NBP Company Descriptions

Werewolf Therapeutics NASDAQ:HOWL

I-Mab NASDAQ:NBP

Organogenesis NASDAQ:ORGO

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools